Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNK3 | O14649 | 4/20 | 0.40 |
| ▸ | KCNK9 | Q9NPC2 | 4/20 | 0.40 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.39 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.39 |
| ▸ | MGLL | Q99685 | 1/20 | 0.38 |
| ▸ | PNLIP | P16233 | 1/20 | 0.37 |
| ▸ | GRIN2B | Q13224 | 2/20 | 0.37 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.37 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.36 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.36 |
| ▸ | F2R | P25116 | 1/20 | 0.36 |
| ▸ | ANO1 | Q5XXA6 | 2/20 | 0.36 |
| ▸ | GAA | P10253 | 1/20 | 0.35 |
| ▸ | RXRA | P19793 | 1/20 | 0.35 |
| ▸ | RXRB | P28702 | 1/20 | 0.35 |
| ▸ | RXRG | P48443 | 1/20 | 0.35 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.34 |
| ▸ | HCRTR1 | O43613 | 1/20 | 0.34 |
| ▸ | HCRTR2 | O43614 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1106365 | 1.00 | KCNK3 (0.40) | KCNK3KCNK9CYP11B1CYP11B2ALDH1A1 | |
| SCHEMBL9951788 | 1.00 | KCNK3 (0.40) | KCNK3KCNK9CYP11B1CYP11B2ALDH1A1 | |
| SCHEMBL16502057 | 0.79 | KCNK3 (0.43) | KCNK3KCNK9CYP11B1CYP11B2ALDH1A1 | |
| SCHEMBL23761699 | 0.79 | ANO1 (0.44) | KCNK3KCNK9CYP11B1CYP11B2ALDH1A1 | |
| SCHEMBL102459 | 0.79 | GAA (0.42) | KCNK3KCNK9CYP11B1CYP11B2ALDH1A1 | |
| SCHEMBL102458 | 0.79 | GAA (0.42) | KCNK3KCNK9CYP11B1CYP11B2ALDH1A1 | |
| SCHEMBL249223 | 0.78 | KCNK3 (0.49) | KCNK3KCNK9CYP11B1CYP11B2ALDH1A1 | |
| SCHEMBL12954616 | 0.78 | KCNK3 (0.42) | KCNK3KCNK9CYP11B1CYP11B2ALDH1A1 | |
| SCHEMBL2120412 | 0.76 | CA1 (0.46) | KCNK3KCNK9ALDH1A1L3MBTL1 | |
| SCHEMBL30210823 | 0.76 | CA1 (0.46) | KCNK3KCNK9ALDH1A1L3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 51 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12611401-B2 | Combinations comprising benzodioxol as GLP-1R agonists for use in the treatment of NASH/NAFLD and related diseases | PFIZER INC. (US) | 2026-04-28 | — | — | US | disclosed |
| EP-3972596-B1 | COMBINATIONS COMPRISING BENZODIOXOL AS GLP-1R AGONISTS FOR USE IN THE TREATMENT OF NASH/NAFLD AND RELATED DISEASES | PFIZER (US) | 2025-07-16 | — | — | EP | disclosed |
| US-11912674-B2 | Isoxazole derivatives as nuclear receptor agonists and uses thereof | IL DONG PHARMACEUTICAL CO., LTD. (KR) | 2024-02-27 | — | — | US | disclosed |
| EP-3650449-B1 | FXR RECEPTOR AGONIST | XUANZHU BIOPHARMACEUTICAL CO LTD (CN) | 2023-08-23 | — | — | EP | disclosed |
| CN-112876467-B | FXR receptor agonists | 轩竹生物科技股份有限公司 | 2023-06-16 | — | — | CN | disclosed |
| US-20230096663-A1 | FARNESOID X RECEPTOR MODULATING COMPOUNDS AND METHODS OF USING THE SAME | INORBIT THERAPEUTICS AB (SE) | 2023-03-30 | — | — | US | disclosed |
| EP-4106746-A1 | FARNESOID X RECEPTOR MODULATING COMPOUNDS AND METHODS OF USING THE SAME | INORBIT THERAPEUTICS AB (SE) | 2022-12-28 | — | — | EP | disclosed |
| US-20220387402-A1 | COMBINATIONS COMPRISING BENZODIOXOL AS GLP-1R AGONISTS FOR USE IN THE TREATMENT OF NASH/NAFLD AND RELATED DISEASES | PFIZER INC. (US) | 2022-12-08 | — | — | US | disclosed |
| US-11352358-B2 | FXR agonist | Xuanzhu Biopharmaceutical Co., Ltd. (CN) | 2022-06-07 | — | — | US | disclosed |
| US-11339153-B2 | Compounds useful in modulating the farnesoid X receptor and methods of making and using the same | INORBIT THERAPEUTICS AB (SE) | 2022-05-24 | — | — | US | disclosed |
| EP-2655369-A1 | COMPOSITIONS AND METHODS FOR MODULATING FARNESOID X RECEPTORS | IRM LLC (BM) | 2013-10-30 | — | — | EP | disclosed |
| EP-2655370-A1 | COMPOSITIONS AND METHODS FOR MODULATING FXR | IRM LLC (BM) | 2013-10-30 | — | — | EP | disclosed |
| CN-103370315-A | Compositions and methods for modulating farnesoid x receptors | IRM LLC | 2013-10-23 | — | — | CN | disclosed |
| US-20130261108-A1 | COMPOSITIONS AND METHODS FOR MODULATING FARNESOID X RECEPTORS | IRM LLC (BM) | 2013-10-03 | — | — | US | disclosed |
| WO-2012144752-A1 | PHENYL-ISOXAZOL DERIVATIVES AND PREPARATION PROCESS THEREOF | IL-YANG PHARM. CO., LTD. (KR) | 2012-10-26 | — | — | WO | disclosed |
| WO-2012087519-A1 | COMPOSITIONS AND METHODS FOR MODULATING FXR | IRM LLC (BM) | 2012-06-28 | — | — | WO | disclosed |
| WO-2012087520-A1 | COMPOSITIONS AND METHODS FOR MODULATING FARNESOID X RECEPTORS | IRM LLC (BM) | 2012-06-28 | — | — | WO | disclosed |
| WO-2012087521-A1 | COMPOSITIONS AND METHODS FOR MODULATING FARNESOID X RECEPTORS | IRM LLC (BM) | 2012-06-28 | — | — | WO | disclosed |
| US-20110034507-A1 | FARNESOID X RECEPTOR AGONISTS | SMITHKLINE BEECHAM CORPORATION (US) | 2011-02-10 | — | — | US | disclosed |
| EP-1456182-B1 | PYRIMIDINE DERIVATIVES AS MODULATORS OF INSULINE-LIKE GROWTH FACTOR-1 RECEPTOR (IGF-I) | ASTRAZENECA AB (SE) | 2009-03-11 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11339153-B2 | Compounds useful in modulating the farnesoid X receptor and methods of making and using the same | NR1H4, SLC10A2, FXR2 | KCNK3 4357/4885KCNK9 4557/4885CYP11B1 74/4885 |
| US-20230096663-A1 | FARNESOID X RECEPTOR MODULATING COMPOUNDS AND METHODS OF USING THE SAME | NR1H4, NR1H3, NR1H2 | KCNK3 4633/4885KCNK9 4751/4885CYP11B1 37/4885 |
| US-20220387402-A1 | COMBINATIONS COMPRISING BENZODIOXOL AS GLP-1R AGONISTS FOR USE IN THE TREATMENT OF NASH/NAFLD AND RELATED DISEASES | GLP1R, GCKR, GCGR | KCNK3 484/4885KCNK9 527/4885CYP11B1 702/4885 |
| US-20130261108-A1 | COMPOSITIONS AND METHODS FOR MODULATING FARNESOID X RECEPTORS | NR1H4, SLC10A1, GPBAR1 | KCNK3 4202/4885KCNK9 4395/4885CYP11B1 23/4885 |
| US-20110034507-A1 | FARNESOID X RECEPTOR AGONISTS | NR1H4, NR1H3, NR1H2 | KCNK3 3741/4885KCNK9 4402/4885CYP11B1 70/4885 |
| US-11352358-B2 | FXR agonist | NR1H4, FXR1, NR1H3 | KCNK3 2682/4885KCNK9 2486/4885CYP11B1 28/4885 |
| US-12611401-B2 | Combinations comprising benzodioxol as GLP-1R agonists for use in the treatment of NASH/NAFLD and related diseases | GLP1R, GCKR, GPR119 | KCNK3 555/4885KCNK9 439/4885CYP11B1 603/4885 |
| US-11912674-B2 | Isoxazole derivatives as nuclear receptor agonists and uses thereof | NR1H4, NR1H3, NR1H2 | KCNK3 2985/4885KCNK9 4210/4885CYP11B1 42/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.